Home Markets FDA reviews GSK’s depemokimab for asthma, CRSwNP; decision due Dec. 16 FDA reviews GSK’s depemokimab for asthma, CRSwNP; decision due Dec. 16 Andrew M Mar 03, 2025 comments off Tweet on Twitter Share on Facebook Google+ Pinterest Original source: https://www.investing.com/news/stock-market-news/fda-reviews-gsks-depemokimab-for-asthma-crswnp-decision-due-dec-16-3901530 Market Updates